Backed by Big Phar­ma VCs, Palleon ramps up a new ap­proach to im­muno-on­col­o­gy with a $48M start­up round

A cou­ple of years ago, GSK’s ven­ture arm SR One brought in Jim Brod­er­ick as its first-ever en­tre­pre­neur-in-res­i­dence. And to­day, they’re back­ing his new can­cer R&D play, help­ing bankroll a $47.6 mil­lion start­up round for his up­start biotech Palleon.

These past two years have in­clud­ed an ed­u­ca­tion in the con­verg­ing roles of gly­co­science and hu­man im­munol­o­gy, Brod­er­ick tells me. Start­ing with ob­ser­va­tions on the vary­ing role of gly­cans in ei­ther ac­ti­vat­ing or brak­ing the im­mune sys­tem, his search in­volved bring­ing to­geth­er some of the top sci­en­tists in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER